Mining The Data: WellPoint Stresses Need For Context In Safety Surveillance
WellPoint is exploring ways to more accurately identify adverse events as it builds a drug safety monitoring system, according to Marcus Wilson, president of the insurer's HealthCore health outcomes subsidiary
You may also be interested in...
FDA's Sentinel post-market safety monitoring project will augment, not replace, the agency's current repertoire of post-market activities and requirements for drugs, Center for Drug Evaluation and Research Director Janet Woodcock emphasized
WellPoint is developing a post-marketing drug safety monitoring system that will be capable of drawing data from the 25 million members in its integrated medical and pharmacy insurance plans
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.